Results

1–7 of 7 results for Suprachoroidal Triamcinolone

Durability and Safety of Suprachoroidal Triamcinolone Acetonide in Eyes with Chronic Cystoid Macular Edema in Real-world Clinical Practice
Sunir J. Garg, MD, FACS, FASRS
Updates from the Field
2026
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Danny A. Mammo, MD
Annual Meeting Talks
2024
Efficacy of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in the Treatment of Macular Edema in Patients With Chronic Uveitis
Christopher R Henry, MD
Annual Meeting Talks
2022
Suprachoroidal Triamcinolone Acetonide Injectable Suspension for Uveitic Macular Edema: Outcomes in PEACHTREE by Baseline Disease Characteristics
On Demand Cases, Courses, and Papers
2022
Office Based Flicker ERG for Monitoring the Course of CRVO and HRVO Treated With Intravitreal Anti-VEGF and Suprachoroidal Triamcinolone Therapy
John J. Wroblewski, MD
Annual Meeting Talks
2021
Intraocular Pressure Following Administration of Suprachoroidal Triamcinolone Acetonide Suspension: Results From the Phase 3 PEACHTREE Clinical Trial
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2020
Suprachoroidal Triamcinolone Acetonide with and without Intravitreal Aflibercept for Diabetic Macular Edema: Results of the 6-Month Prospective, Phase 1/2 Hulk Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2017